Epilepsy Pipeline Assessment, 2023 Updates: FDA, EMA, and PMDA Approvals, Emerging Drugs, Clinical Trials, Therapeutic Analysis, and Growth Prospects | Elium Therapeutics, CombiGene, Ovid Therapeutics

Epilepsy Pipeline Assessment, 2023 Updates: FDA, EMA, and PMDA Approvals, Emerging Drugs, Clinical Trials, Therapeutic Analysis, and Growth Prospects | Elium Therapeutics, CombiGene, Ovid Therapeutics
(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Epilepsy pipeline constitutes 75+ key companies continuously working towards developing 90+ Epilepsy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Epilepsy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.


Epilepsy Pipeline Insight, 2023 report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Epilepsy Market


Some of the key takeaways from the Epilepsy Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Epilepsy treatment therapies with a considerable amount of success over the years. 

  • Epilepsy companies working in the treatment market are Elium Therapeutics, CombiGene, Ovid Therapeutics, Otsuka Pharmaceutical Co.,Ltd., SK Biopharmaceuticals, Receptor Life Sciences, Cerebral Therapeutics, Equilibre Biopharmaceuticals, Cerevel Therapeutics, Engrail Therapeutics, Amzell, Xenon Pharmaceuticals Inc., and others, are developing therapies for the Epilepsy treatment 

  • Emerging Epilepsy therapies in the different phases of clinical trials are- Kv7 Program, CG 01, OV329, OPC-214870, SKL24741, RLS103, CT-010, EQU 001, Darigabat, ENX-101, AMZ002, XEN496, and others are expected to have a significant impact on the Epilepsy market in the coming years.   

  • In January 2023, Amzell started an open-label, randomized superiority study to assess the safety and effectiveness of AMZ002 in treating infantile spasms, a rare form of epilepsy. This study’s primary goal is to examine the effectiveness of AMZ002 with Vigabatrin in treating patients with recently diagnosed infantile spasms (IS).

  • In March 2023, A pharmaceutical company in preclinical stages, IAMA Therapeutics is dedicated to finding, developing, and commercializing innovative treatments to improve the lives of people with brain disorders. Recently, the company announced that preclinical data supporting its IAMA-6 program in focal refractory epilepsy will be presented at the 75th American Academy of Neurology (AAN) Annual Meeting, which will be held in Boston, Massachusetts, from April 22–27.

  • In February 2023, Addex Therapeutics declared that the Phase 2 clinical study on ADX71149 (JNJ-40411813) for the treatment of epilepsy had reached the completion of enrollment in Part 1. Allosteric modulator (PAM) ADX71149 is a selective metabotropic glutamate type 2 (mGlu2) receptor-positive agent. The trial is being carried out by Janssen Pharmaceuticals, Inc., a division of Johnson & Johnson’s Janssen Pharmaceutical Companies.

  • In January 2023, Positive topline results from a Phase 2 clinical trial assessing the clinical safety, tolerability, and initial efficacy of EQU-001, a novel anti-inflammatory anti-seizure medication, were reported by Equilibre Biopharmaceuticals Corp. EQU-001 is administered orally once daily as an adjunctive therapy for focal seizures in adults with epilepsy. The EQU-001 study’s results are promising for adult patients with focal epilepsy, particularly for those with challenging-to-treat seizures, as they show remarkable tolerance and excellent efficacy.

  • In January 2023, An innovative electronic diary (eDiary) data capturing system was unveiled by Signant Health with the goal of streamlining the epilepsy trial experience for patients and research sites while guaranteeing reliable outcome assessment data to support trial outcomes. The new patient-reported outcome measure, created in partnership with The Epilepsy Study Consortium (TESC), provides organizations and sponsors of clinical research with a standardized way to collect high-quality data on common seizure data items.

  • In June 2022, Preclinical research from CODA Biotherapeutics, Inc.’s focal epilepsy program showed that therapy with the company’s lead-engineered receptor and small molecule activator medication greatly decreased the frequency of focal seizures in vivo. The quick decrease in seizures, according to the results, is in line with the activator drug’s pharmacokinetics in animal models. Data also showed a strong correlation between a decrease in the frequency of seizures and the expression of the primary receptor on CODA.

  • In September 2022, With great pleasure, Avicanna Inc. announced that it has extended its epilepsy research collaboration by joining forces with the University of Toronto and the research team of Dr. Mac Burnham to investigate the effectiveness of Avicanna’s patented formulations in pre-clinical epilepsy models. The research cooperation headed by the group of Dr. Mac Burnham will investigate the effectiveness of Avicanna’s medication candidates in animal models of epilepsy, including AVCN319302.

  • In December 2022, Praxis Precision Medicines, Inc. and UCB have established a strategic partnership to find small molecule therapies as possible treatments for epilepsies associated to KCNT1. The partnership is based on Praxis’ PRAX-020 initiative. As per the agreement, UCB holds the sole right to grant an exclusive worldwide license for the development and commercialization of any resulting small molecule development candidate, including KCNT1.

  • In January 2022, AstraZeneca and Ovid Therapeutics Inc. have established an exclusive licensing arrangement for a library of early-stage small compounds, including lead candidate OV350, that target the KCC2 transporter. The business aims to expedite and optimize the development of these KCC2 transporter activators for use in neuropathic diseases, possibly including epilepsies.


Epilepsy Overview

A chronic neurological illness called epilepsy is typified by recurrent, frequent seizures that cause atypical behavior. Because the causes, severity, and types of seizures vary, it may be classified as a spectrum disorder. The disorder known as epilepsy is characterized by abnormal or excessive electrical discharges from brain cells that impair brain function.


Get a Free Sample PDF Report to know more about Epilepsy Pipeline Therapeutic Assessment-



Emerging Epilepsy Drugs Under Different Phases of Clinical Development Include:

  • Kv7 Program: Elium Therapeutics

  • CG 01: CombiGene

  • OV329: Ovid Therapeutics

  • OPC-214870: Otsuka Pharmaceutical Co.,Ltd.

  • SKL24741: SK Biopharmaceuticals

  • RLS103: Receptor Life Sciences

  • CT-010: Cerebral Therapeutics

  • EQU 001: Equilibre Biopharmaceuticals

  • Darigabat: Cerevel Therapeutics

  • ENX-101: Engrail Therapeutics

  • AMZ002: Amzell

  • XEN496: Xenon Pharmaceuticals Inc.


Epilepsy Route of Administration

Epilepsy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Oral

  • Intravenous

  • Subcutaneous

  • Parenteral

  • Topical


Epilepsy Molecule Type

Epilepsy Products have been categorized under various Molecule types, such as

  • Recombinant fusion proteins

  • Small molecule

  • Monoclonal antibody

  • Peptide

  • Polymer

  • Gene therapy 


Epilepsy Pipeline Therapeutics Assessment

  • Epilepsy Assessment by Product Type

  • Epilepsy By Stage and Product Type

  • Epilepsy Assessment by Route of Administration

  • Epilepsy By Stage and Route of Administration

  • Epilepsy Assessment by Molecule Type

  • Epilepsy by Stage and Molecule Type


DelveInsight’s Epilepsy Report covers around 90+ products under different phases of clinical development like

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I)

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

  • Route of Administration


Further Epilepsy product details are provided in the report. Download the Epilepsy pipeline report to learn more about the emerging Epilepsy therapies


Some of the key companies in the Epilepsy Therapeutics Market include:

Key companies developing therapies for Epilepsy are – Alexza Pharmaceuticals, Xenon Pharmaceuticals, GW Pharmaceuticals, Equilibre Biopharmaceuticals, Takeda Pharmaceuticals, Abide therapeutics, Otsuka pharmaceutical, H. Lundbeck A/S, Spark Therapeutics,  Equilibre Biopharmaceuticals,  ES Therapeutics, Supernus Pharmaceuticals, Inc., MGC Pharmaceuticals, Engrail Therapeutics INC, SK biopharmaceuticals, Longboard Pharmaceuticals, Janssen Research & Development, LLC, Equilibre Biopharmaceuticals, Cerevel Therapeutics, LLC, Neurona Therapeutics, Praxis Precision Medicines, UCB Pharma, Receptor Life Sciences, and others.


Epilepsy Pipeline Analysis:

The Epilepsy pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Epilepsy with aggregate therapies developed by each company for the same.

  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Epilepsy Treatment.

  • Epilepsy key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • Epilepsy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Epilepsy market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.


Download Sample PDF Report to know more about Epilepsy drugs and therapies


Epilepsy Pipeline Market Drivers

  • Rising awareness and strategic alliance, increasing launch of novel drugs, high burden of epilepsy are some of the important factors that are fueling the Epilepsy Market.


Epilepsy Pipeline Market Barriers

  • However, loss of patent protection for branded drugs, high cost of treatment and other factors are creating obstacles in the Epilepsy Market growth.


Scope of Epilepsy Pipeline Drug Insight    

  • Coverage: Global

  • Key Epilepsy Companies: Elium Therapeutics, CombiGene, Ovid Therapeutics, Otsuka Pharmaceutical Co.,Ltd., SK Biopharmaceuticals, Receptor Life Sciences, Cerebral Therapeutics, Equilibre Biopharmaceuticals, Cerevel Therapeutics, Engrail Therapeutics, Amzell, Xenon Pharmaceuticals Inc., and others

  • Key Epilepsy Therapies: Kv7 Program, CG 01, OV329, OPC-214870, SKL24741, RLS103, CT-010, EQU 001, Darigabat, ENX-101, AMZ002, XEN496, and others

  • Epilepsy Therapeutic Assessment: Epilepsy current marketed and Epilepsy emerging therapies

  • Epilepsy Market Dynamics: Epilepsy market drivers and Epilepsy market barriers 


Request for Sample PDF Report for Epilepsy Pipeline Assessment and clinical trials


Table of Contents

1. Epilepsy Report Introduction

2. Epilepsy Executive Summary

3. Epilepsy Overview

4. Epilepsy- Analytical Perspective In-depth Commercial Assessment

5. Epilepsy Pipeline Therapeutics

6. Epilepsy Late Stage Products (Phase II/III)

7. Epilepsy Mid Stage Products (Phase II)

8. Epilepsy Early Stage Products (Phase I)

9. Epilepsy Preclinical Stage Products

10. Epilepsy Therapeutics Assessment

11. Epilepsy Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Epilepsy Key Companies

14. Epilepsy Key Products

15. Epilepsy Unmet Needs

16 . Epilepsy Market Drivers and Barriers

17. Epilepsy Future Perspectives and Conclusion

18. Epilepsy Analyst Views

19. Appendix

20. About DelveInsight


About DelveInsight


DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services